Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

NCT ID: NCT06533761

This clinical trial is studying a new treatment called eganelisib, both on its own and in combination with another medication called cytarabine. The focus is on patients with relapsed or refractory...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States, Duarte, California, United States +10 more

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

NCT ID: NCT01861106

This clinical trial is looking at how effective stem cell transplants are for treating people with GATA2 mutations, which can lead to serious health issues like immunodeficiency and certain types o...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States, Bethesda, Maryland, United States

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

NCT ID: NCT07006025

This clinical trial is exploring a new treatment for patients with relapsed or refractory myelodysplastic syndromes (MDS), a type of blood disorder. The study will test the combination of two drugs...

Recruiting

Phase: PHASE1 Type: interventional Locations: Bronx, New York, United States

Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy

NCT ID: NCT06895538

This clinical trial is studying the effects of a treatment called rabbit anti-human T-lymphocyte immunoglobulin (ATLG) compared to another treatment called anti-thymocyte globulin (ATG) for patient...

Recruiting

Type: observational Locations: Beijing, , China

Global Registry and Natural History Study for Mitochondrial Disorders

NCT ID: NCT05554835

The Global Registry and Natural History Study for Mitochondrial Disorders is a research project aimed at understanding various mitochondrial diseases, which are conditions that affect how our cells...

Recruiting

Type: observational Locations: Münster, , Germany, Innsbruck, , Austria +18 more

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

NCT ID: NCT06326463

This clinical trial is studying a new treatment called CAR T-cell therapy specifically for young patients (up to 21 years old) who have certain hard-to-treat blood cancers, such as acute myelogenou...

Recruiting

Phase: PHASE1 Type: interventional Locations: Memphis, Tennessee, United States

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

NCT ID: NCT05829226

This clinical trial is studying a new treatment called LYT-200 for adults with relapsed or refractory Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). In simple terms, this...

Recruiting

Phase: PHASE1 Type: interventional Locations: Orange, California, United States, Providence, Rhode Island, United States +15 more

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

NCT ID: NCT06972641

This clinical trial is studying how different genetic factors can influence the best maintenance therapy after patients receive a stem cell transplant for conditions like acute myeloid leukemia (AM...

Recruiting

Phase: PHASE2 Type: interventional Locations: Shanghai, Shanghai, China

A Long Term Follow-up Study of TScan TCR-T Products

NCT ID: NCT06976736

This clinical trial, called the Long Term Follow-Up Study of TScan TCR-T Products, aims to keep a close eye on patients who have previously received special treatments known as TCR-T therapies (spe...

Not yet recruiting

Type: observational Locations: Duarte, California, United States, New York, New York, United States

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

NCT ID: NCT05582902

The PRO-RED study is a clinical trial designed to understand how patients with lower-risk myelodysplastic syndromes (MDS) experience their condition and treatment, particularly regarding their qual...

Recruiting

Type: observational Locations: Düsseldorf, , Germany, Leipzig, , Germany +12 more

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT ID: NCT05181735

This clinical trial is studying a combination treatment using a medication called luspatercept for patients with low-risk myelodysplastic syndromes (LR-MDS) who do not have ring sideroblasts. This ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Rouen, , France, Argenteuil, , France +42 more

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

NCT ID: NCT05226455

This clinical trial is testing a new treatment combining two medications, venetoclax and azacitidine, along with a procedure called donor lymphocyte infusion (DLI). It is aimed at patients who have...

Recruiting

Phase: PHASE1 Type: interventional Locations: Rouen, , France, Paris, , France +12 more

Familial Investigations of Childhood Cancer Predisposition

NCT ID: NCT03050268

This clinical trial, called "Familial Investigations of Childhood Cancer Predisposition," is studying how certain genetic factors may increase the risk of developing specific types of childhood can...

Recruiting

Type: observational Locations: Memphis, Tennessee, United States

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

NCT ID: NCT06156579

This clinical trial is studying a new treatment approach for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have not responded to standard chemotherapy or have re...

Recruiting

Phase: PHASE2 Type: interventional Locations: Tuebingen, Baden Wuerttemberg, Germany

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

NCT ID: NCT06704152

This clinical trial is studying a new treatment called BSB-1001 for patients with certain types of blood cancers, specifically Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or M...

Recruiting

Phase: PHASE1 Type: interventional Locations: Ann Arbor, Michigan, United States, Minneapolis, Minnesota, United States +3 more

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

NCT ID: NCT05796570

This clinical trial is looking at a new treatment approach for children and young adults who have certain blood cancers, including Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +2 more

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

NCT ID: NCT06765928

This clinical trial is looking at the effectiveness and safety of a combination treatment—selinexor and venetoclax—for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) ...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Shanghai, Shanghai, China

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

NCT ID: NCT04187105

The BMT-06 clinical trial is studying a treatment approach called Intensity Modulated Total Marrow Irradiation (IM-TMI) for patients with acute leukemia or myelodysplastic syndromes (MDS). This tre...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States

National Longitudinal Cohort of Hematological Diseases

NCT ID: NCT04645199

The National Longitudinal Cohort of Hematological Diseases study is looking to better understand various blood-related conditions, such as multiple myeloma, acute myeloid leukemia, and hemophilia, ...

Recruiting

Type: observational Locations: Tianjin, Tianjin, China

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT ID: NCT05476770

This clinical trial is studying a new treatment called tagraxofusp for children and young adults with certain types of blood cancers that have not responded to previous treatments. Tagraxofusp work...

Recruiting

Phase: PHASE1 Type: interventional Locations: Philadelphia, Pennsylvania, United States, New York, New York, United States +29 more

Main Menu

Clinical Trials for MDS

34 Active Trials Found

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy

Global Registry and Natural History Study for Mitochondrial Disorders

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

A Long Term Follow-up Study of TScan TCR-T Products

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Familial Investigations of Childhood Cancer Predisposition

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

National Longitudinal Cohort of Hematological Diseases

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Related Conditions